Immune checkpoint inhibitors(ICI)are a major breakthrough in oncology treatment and are in-creasingly used in clinical practice.ICI-associated myocarditis is one of the rare adverse reactions to ICI drugs,with a high mortality rate.Guidelines for treating this adverse reaction have been written both domestically and in-ternationally at home and abroad.However,there is still a lack of awareness and reliable regulatory assessment protocols in clinical work.Therefore,this article reviews the pathogenesis,diagnosis,and treatment strategies of ICI-associated myocarditis in order to raise the awareness of oncologists and cardiologists.
NETL
NSTL
万方数据
